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Abstract
 
Various immune diseases are considered to be regulated by the balance of T helper (Th)1 and
Th2 subsets. Although Th lymphocytes are believed to be generated in draining lymph nodes
(LNs), in vivo Th cell behaviors during Th1/Th2 polarization are largely unexplored. Using a
 
murine granulomatous liver disease model induced by 
 
Propionibacterium acnes
 
, we show that re-
tention of Th1 cells in the LNs is controlled by a chemokine, CXCL10/interferon (IFN) in-
ducible protein 10 produced by mature dendritic cells (DCs). Hepatic LN DCs preferentially
produced CXCL10 to attract 5
 
 
 
-bromo-2
 
 
 
-deoxyuridine (BrdU)
 
 
 
CD4
 
 
 
 T cells and form
 
clusters with IFN-
 
 
 
–producing CD4
 
 
 
 T cells by day 7 after antigen challenge. Blockade
of CXCL10 dramatically altered the distribution of cluster-forming BrdU
 
 
 
CD4
 
 
 
 T cells.
BrdU
 
 
 
CD4
 
 
 
 T cells in the hepatic LNs were selectively diminished while those in the circula-
tion were significantly increased by treatment with anti-CXCL10 monoclonal antibody. This was
accompanied by accelerated infiltration of memory T cells into the periphery of hepatic granu-
loma sites, most of them were in cell cycle and further produced higher amount of IFN-
 
 
 
 leading
to exacerbation of liver injury. Thus, mature DC-derived CXCL10 is pivotal to retain Th1 lym-
phocytes within T cell areas of draining LNs and optimize the Th1-mediated immune responses.
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Introduction
 
Systemic recirculation of T lymphocytes is necessary to
maintain constant surveillance of host tissues (1, 2) and is
largely dependent on various chemokines based on their
state of differentiation and level of activation (3–6). When
naive CD4
 
 
 
 T cells encounter an appropriate antigen pre-
sented by mature dendritic cells (DCs)
 
*
 
 in the paracortex of
LNs, they enter the cell cycle and presumably differentiate
into memory/effector T cells, such as nonpolarized T, and
subsequently Th1, or Th2 cells (7–11). DC–T cell interac-
tion is therefore considered to be essential to initiate effec-
tor T cell generation (1, 7, 12). To undergo proper func-
tion, antigen-primed CD4
 
 
 
 T cells migrate through
LNs during immune responses. CC chemokine receptor
(CCR)7
 
 
 
 T cells may remain within T cell areas (6),
CCR4
 
 
 
 T cells seem to migrate toward a new wave of ma-
turing DCs within the paracortex (13), CXCR5
 
 
 
 follicular
Th cells move to the follicular border to interact with B
cells (14), and other T cells return to the circulation
through efferent lymphatics (4, 5, 11). However, the in
vivo evidence to support those events is confined to rather
early stages within the first 48 h after stimulation (6–8, 12–
14), while T cells are characteristically in a nonpolarized
proliferative stage. The actual site of subsequent Th1 or
Th2 polarization, and the mediators regulating the migra-
tory patterns of polarized T cell are still ill-defined (11).
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Th1 Retention by CXCL10
 
Mature DCs express a set of chemokines (15, 16),
which enable them to attract various subsets of T cells and
thus to promote and amplify DC–T cell interactions.
However, there is very limited evidence concerning the
roles of DC-derived chemokines in DC–T cell interaction
in the lymphoid organs. IFN-inducible protein (IP)-10/
CXCL10 has been reported to be an inflammatory
chemokine, which is induced by proinflammatory stimuli
(17–19) and may attract effector Th1 cells to sites of local
inflammation (20–22). We described previously that
CXCL10 is expressed at not only by nonlymphoid organs
such as liver and kidney (17–19, 22) but also by lymphoid
organs such as spleen and thymus (23). Therefore, we
thought that CXCL10 might play a role in the lymphoid
organs. We investigated herein the role of CXCL10 in
LNs administered with 
 
Propionibacterium acnes
 
, which is
suspected to cause sarcoidosis in humans (24) and induces
a granulomatous liver disease in mice (22, 25).
 
Materials and Methods
 
Characterization of Anti-CXCL10 mAb.
 
Anti–rat CXCL10
mAb was generated as described previously (13). To test whether
this mAb could inhibit the function of murine CXCL10 (R&D
Systems), we performed chemotaxis assay of the splenocytes ob-
tained from C57BL/6 mice with concanavalin A–induced hepati-
tis (18, 23) and calcium influx assay using murine CXCR3 stably
transfected CHO-K1 cells (23). 100 
 
 
 
g/ml of this mAb could
50% block the activity of murine CXCL10 (100 ng/ml) in
chemotaxis and completely block calcium influx assays. The spec-
ificity of this mAb for CXCL10 was confirmed immunologically
against murine CXCL9, CCL3, CCL21, and CCL22.
 
In Vivo Treatment.
 
Specific pathogen-free female C57BL/6
mice (8–9 wk old; CLEA Japan, Inc.) were injected with heat-
killed 
 
P. acnes
 
 (ATCC 11828; 1 mg/100 
 
 
 
l in PBS) via the tail
vein (22, 25). All mice were injected with 5
 
 
 
-bromo-2
 
 
 
-deoxy-
uridine (BrdU) (500 
 
 
 
g/100 
 
 
 
l PBS; Sigma-Aldrich) 1 h before
killing (25). For blocking experiments, 200 
 
 
 
g/100 
 
 
 
l in PBS of
anti-CXCL10 mAb or anti–human parathyroid-related peptide
mAb, which was the IgG1 subclass-matched control mAb, or
anti-CXCL9 pAb, anti-CCL3 pAb (25), or control rabbit IgG
(25) were administered 0–2 d after 
 
P. acnes
 
 injection. Hepatocel-
lular damage was determined by serum alanine transferase levels
(22). All animal experiments complied with the standards set out
in the guidelines of The University of Tokyo.
 
Immunostaining.
 
The following anti–mouse mAbs were used:
CD3
 
 
 
 (clone; 145–2C11); CD4 (RM4–5); B220 (RA3–6B2);
CD62L (MEL-14); IFN-
 
 
 
 (XMG1.2; BD PharMingen); DEC-
205 (NLDC-145) (BMA BIOMEDICALS); and CD11c (N418;
Serotec). As secondary Abs, an alkaline phosphatase–labeled
anti–rat IgG (Jackson ImmunoResearch Laboratories) and a
horseradish peroxidase–labeled anti–rat Ig (Biosource) were
used. For immunostaining of CXCL10 or CXCL9, goat pAbs
(25) to CXCL10 or CXCL9 (Santa Cruz Biotechnology, Inc.)
were used.
Single or triple immunostaining was performed by indirect im-
munoalkaline phosphatase or immunoperoxidase methods (25).
For triple immunostaining, acetone-fixed 6-
 
 
 
m fresh frozen tis-
sue sections were doubly immunostained using 3,3
 
 
 
-diaminoben-
zidine (DAB; Wako) substrate solution and alkaline phosphatase
substrate kit II (Vector blue; Vector Laboratories). After further
 
fixation with 1% glutaraldehyde (Nakarai) in PBS for 9 min, they
were reacted with the third Abs to BrdU using a BrdU staining
kit (Zymed) and were colored red with Vector Red (25).
For double immunofluorescence staining, acetone-fixed 4-
 
 
 
m
fresh frozen tissue sections were incubated with biotinylated anti-
CD4/B220 or DEC-205 mAbs and then with Alexa-594-conju-
gated avidin (Molecular Probes). They were incubated with
FITC-conjugated anti–IFN-
 
 
 
 mAb or anti-CXCL10 followed
by FITC-labeled anti–goat IgG (26), and were observed by fluo-
rescence microscopy (26).
 
Preparation of CD11c
 
 
 
 DCs.
 
For liver, nonparenchymal cells
were first prepared as described previously (25). Flow cytometric
immunofluorescence analyses of freshly isolated nonparenchymal
cells were performed and CD11c
 
 
 
 cells were sorted using EPICS
ELITE ESP cell sorter (Beckman Coulter) as described previously
(22, 25). To collect circulating CD11c
 
 
 
 DC precursors (25), pe-
ripheral blood (0.8 ml) was obtained by cardiac puncture under
ether anesthesia. After density separation (Lympholyte-Mouse;
Cedarlane), immunofluorescence analyses were performed and
B220
 
 
 
CD11c
 
 
 
 cells were sorted (22, 25). LN cells were prepared
as described previously (22). Reanalysis of the sorted population
showed purity 
 
 
 
99%.
The one-way mixed leukocyte reaction for CD11c
 
 
 
 DCs was
also performed in 96-well plates using premix WST-1 cell prolif-
eration assay system (Takara Biomedicals), as described previously
(25). In brief, C57BL/6 mouse derived LN DCs (10
 
4
 
 cells/100
 
 
 
l/well) were cocultured with nylon-wool passed LN T cells
(4 
 
 
 
 10
 
5
 
 cells/100 
 
 
 
l/well) from BALB/c mice for 72 h. 4 h be-
fore the end of culture, WST-1 (20 
 
 
 
l) was added and the absor-
bance (450–650 nm) was measured.
 
Antigen-specific Proliferation.
 
In vitro cell proliferation assay was
performed as described previously (27). Briefly, hepatic LN cells
(10
 
6
 
 cells/100 
 
 
 
l/well) from normal and 
 
P. acnes
 
-primed mice at
days 2 and 7 were stimulated with or without antigens (
 
P. acnes
 
 and
OVA; 10 
 
 
 
g/100 
 
 
 
l of PBS) at 37
 
 
 
C for 72 h. After incubation,
cell proliferation was measured by WST-1 as described previously.
 
RT-PCR.
 
Total RNA was isolated from liver, spleen, and
LN specimens and 2 
 
 
 
 10
 
5
 
 sorted blood, liver, and LN CD11c
 
 
 
cells using RNAzol
 
B
 
 (BIOTEX LAB) and reverse transcribed
(22, 25). Thereafter, cDNA was amplified using the ABI 7700 se-
quence detector system (Applied Biosystems) with a set of prim-
ers and probes corresponding to CXCL9, CXCL10, CXCL11,
CCL3, CCL19, CCL21, CCL22, CXCR3, and GAPDH as de-
scribed previously (22, 25).
 
Chemotaxis Assay.
 
Freshly isolated hepatic LN cells (8 
 
 
 
 10
 
5
 
/
120 
 
 
 
l in RPMI 1640 medium plus 0.25% BSA) were loaded
into murine type IV collagen-coated transwells (3-
 
 
 
m pore size;
Becton Dickinson), which were placed in a 24-well tissue culture
plate containing 500 
 
 
 
l of the medium supplemented with or
without 100 ng/ml of CCL22, CXCL10 (R&D Systems), or
CCL21 (25, 27). 4 h later, cells in the bottom of each well were
collected and counted. After double immunostaining for BrdU
and CD4, the absolute number of migrated BrdU
 
 
 
/
 
 
 
CD4
 
 
 
 cells
was determined by multiplying the total migrated cell number by
the fraction of BrdU
 
 
 
/
 
 
 
CD4
 
 
 
 population.
 
Cytokine Measurement.
 
Liver and hepatic LN CD4
 
 
 
 T cells
were sorted as described previously (22) by an EPICS Elite Cell
Sorter™. Freshly sorted CD4
 
 
 
 T cells (10
 
5
 
 cells per well per 200
 
 
 
l) were incubated in 96-well plates for 24 h with medium or
coated anti-CD3
 
 
 
 mAb (20 
 
 
 
g/ml; reference 22). The levels of
IFN-
 
 
 
 and IL-4 in each culture supernatant were measured by
ELISA kits (Endogen). The detection limits of the assay for IFN-
 
 
 
and IL-4 were 15 and 5 pg/ml, respectively. 
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Statistical Analysis.
 
Differences were evaluated using the Stu-
dent’s 
 
t
 
 test. 
 
P
 
 
 
  
 
0.05 were considered to be statistically significant.
 
Results
 
Production of CXCL10 by Mature DCs in the Paracortex of
Hepatic LNs.
 
We have recently reported the rapid ap-
pearance of CD11c
 
 
 
 DC precursors in the circulation after
 
P. acnes
 
 administration. These DC precursors rapidly mi-
grated into Disse’s space of the liver to participate in gran-
uloma formation, and after their maturation into the he-
patic LNs (25). On the presumption that DCs need to
attract T cells to promote immune response after arriving
at the hepatic LNs, we examined the kinetics of chemo-
kine mRNA expression profiles of LN CD11c
 
 
 
 DCs. In
the early phase (day 2), CD11c
 
 
 
 DCs in the hepatic LNs
started to express CXCL10 and monocyte-derived chemo-
kine (MDC)/CCL22 (Fig. 1 a). In contrast at a later phase
(day 7), these DCs expressed CXCL10 at higher level (Fig.
1, a and b), but not Mig/CXCL9, I-TAC/CXCL11, or
ELC/CCL19 (Fig. 1 a). The expression levels of CCL22
were conversely decreased (Fig. 1 b). CXCL10 was selec-
tively expressed by hepatic LN DCs, but not by circulating
DC precursors or by liver infiltrating mature DCs (Fig. 1
c). In addition, nonregional axillary LN DCs did not ex-
press CXCL10 (Fig. 1 c), suggesting that CXCL10 expres-
sion was not a property common to LN-resident DCs, but
was confined to draining LN DCs. Double immunohis-
tochemical staining confirmed the production of CXCL10
 
by DEC-205
 
 
 
 mature DCs (25) in the paracortex of he-
patic LNs (Fig. 1 d) only after 
 
P. acnes
 
 injection. These data
suggested that activated CD11c
 
 
 
 DCs produced CXCL10
in response to 
 
P. acnes
 
. Based on the traffic of DCs (25)
and restricted distribution of CXCL10 (Fig. 1 c), most
CXCL10-producing DCs were probably derived from the
liver through afferent lymphatics.
 
Promotion of DC–Th1 Lymphocyte Cluster Formation by
CXCL10.
 
After administration of 
 
P. acnes, DEC-205 
mature DCs accumulated in the paracortex (Fig. 2, a and b)
clustered with CD4  T cells (Fig. 2 b). Part of the CD4  T
cells at the periphery of accumulated DCs were labeled
with BrdU (Fig. 2, b and c), suggesting that CD4  T cells
proliferated at these sites. To characterize the T cell subsets
responding to DC-derived CXCL10, we next investigated
the kinetics of proliferation, cytokine production, and mi-
gration potential of the hepatic LN T cells. The frequency
of BrdU CD4  T cells (per mm2) in the paracortex of he-
patic LNs rapidly increased to a maximum level by day 2
and remained stable thereafter (Fig. 2 d). P. acnes-primed
LN T cells exhibited antigen-specific proliferation by day 2
(Fig. 2 e). Sorted LN CD4  T cells at day 2 produced con-
siderable levels of IFN-  and IL-4 (Fig. 2 f). In contrast, the
IL-4 level was decreased nearly to background while the
IFN-  level was dramatically increased by LN CD4  T
cells at day 7 (Fig. 2 f). These results suggested that
BrdU CD4  T cells on day 2 reflected proliferating, non-
polarized Th cells while BrdU CD4  T cells by day 7 cor-
responded to further polarized Th1 cells. IFN- –producing
Figure 1. Production of CXCL10 by maturing DCs in the hepatic LNs. (a) Kinetics for chemokine expression profiles of hepatic LN CD11c  DCs.
Total RNA of normal spleen specimens was used as positive control. (b) Real time quantitative PCR analysis of CXCL10 and CCL22 mRNA expressions
by hepatic LN CD11c  DCs. Each amount was normalized to the level of GAPDH and the final relative values were expressed relative to calibrators
(references 22 and 25); normalized amount on day 0. C, control. (c) Expression of chemokine mRNAs in CD11c  DCs isolated from the blood, liver,
hepatic, and axillary LNs at day 7 after P. acnes injection. These results represent three independent experiments. (d) Double immunostaining for
CXCL10 (green) and DEC-205 (red) in the hepatic LNs on day 5. Double positive DCs (merge; yellow) were detected selectively within the paracortex.
The outline shows the B cell follicle border as evidenced by B220 staining of serial sections. Scale bars, 40  m; 20  m (insert). F, follicle; PC, paracortex.1260 Th1 Retention by CXCL10
CD4  T cells were selectively detected in the paracortex
(Fig. 2 g) and were located at the periphery of small granu-
lomatous clusters (Fig. 2 g). DEC-205  DCs were actually
clustered with IFN- –producing cells (Fig. 2 g).
In chemotaxis assays, both CXCL10 and CCL22 at-
tracted BrdU CD4  T cells at day 2 (Fig. 3 a). In contrast,
BrdU CD4  T cells at day 7 showed a strong chemotactic
response toward CXCL10, while their response to CCL22
was decreased (Fig. 3 a). BrdU CD4  resting T cells did
not respond to CXCL10 or CCL22, but responded to SLC/
CCL21 throughout (Fig. 3 a), suggesting that these cells are
still CCR7  naive T cells (4, 8). CXCR3, a receptor for
CXCL10, was detected on sorted LN CD4  T cells from
day 2, and the expression level significantly increased there-
after (Fig. 3 b). These observations indicated that CXCL10
exhibited a chemotactic activity to antigen-responding, pro-
liferating CXCR3 CD4  T cells, and that Th1 subset pre-
dominated among these proliferating T cells (Fig. 2 f).
Reduced Cluster Formation in the Paracortex by Blocking
CXCL10. To establish the biological role of CXCL10 in
LN T cell mobilization, we investigated the effect of neu-
tralizing anti-CXCL10 mAb on T cell distribution within
Figure 2. Visualization of DC–T
cell clusters in the hepatic LNs. (a–c)
Triple immunostaining in the he-
patic LNs on days 0 (a) and 7 (b and
c). (a) DEC-205  (brown) cells and a
little number BrdU   (red) CD4 
(blue) cells at day 0. Note that these
cells did not form clusters. (b) Nu-
merous clusters between DEC-205 
(brown) cells and BrdU   (red)
CD4  (blue) cells (arrow) were seen
in the paracortex at day 7. *HEV.
Scale bar, 100  m. (c) Contact be-
tween BrdU  (red) CD4  (blue)
cells and DEC-205  (brown) cells
(arrow) at the periphery of a small
granulomatous cluster. Scale bar,
20   m. (d) The numbers of
BrdU CD4  cells in the paracor-
tex of hepatic LNs determined by
15-mm2 stained cryosections. T cell
area of hepatic LNs was defined by
B220 or CD3  staining (reference
25). (e) Antigen-specific prolifera-
tion of hepatic LN T cells sorted
from normal and P. acnes–primed
mice at day 2. White bar, medium
alone (unstimulated); black bar, P.
acnes–stimulated; striped bar, OVA-
stimulated. (f) IFN-  and IL-4 pro-
ductions by sorted LN CD4  T cells
at day 7. C, medium alone as nega-
tive control. (d–f) Representative
data from five independent experi-
ments. Mean   SD. n   6. Student’s
t test, *P   0.05. (g) Double immu-
nostaining for B220 or CD4 (red)
and IFN-  (green) in the hepatic
LNs on day 7. IFN-   cells were se-
lectively located in the B220  para-
cortex (left). IFN-  CD4  cells
(yellow) were selectively located at
the paracortex. The outlines show
the B cell follicle border. F, follicle;
PC, paracortex. Scale bar, 40  m.
IFN-  CD4  cells (merge; yellow;
white arrowheads) were located at
the periphery of a small granuloma-
tous clusters. Right bottom panel de-
picts double staining for IFN- 
(green) and DEC-205 (red) at day 7.
IFN-   cells (white arrowheads) were
located at the periphery of DEC-205 
DC accumulation. Scale bar, 20  m.1261 Yoneyama et al.
the hepatic LNs. Mice were injected with anti-CXCL10
mAb or control mAb 0 and 2 d after P. acnes treatment. On
day 7, there were very few clusters between DEC-205 
mature DCs and BrdU CD4  T cells in the paracortex of
hepatic LNs (Fig. 4, a and b) and only foci of DCs with rest-
ing T cells were seen in anti-CXCL10 mAb-treated mice
(Fig. 4, a–e). Although the CD4/CD8 ratio (3.52 vs. 3.80
in control mAb versus anti-CXCL10 mAb-treated mice)
and total cell number (Fig. 4 f) of hepatic LNs did not statis-
tically change, the number of BrdU CD4  T cells was sig-
nificantly decreased in anti-CXCL10 mAb-treated mice at
day 7 (Fig. 4, b and g). In situ double immunofluorescence
Figure 3. Migration potential o f LN T
lymphocytes. (a) Chemotaxis of freshly iso-
lated LN T cells. The absolute numbers of
responding cell subsets were determined af-
ter migration as described above, and final
results are presented as percentage of the in-
put cells migrated (reference 23). Resting T,
BrdU CD4  T cells; Proliferating T,
BrdU CD4  T cells; C, medium alone as
negative control. (b) Real time quantitative
PCR analysis of CXCR3 mRNA expression
on freshly isolated LN CD4  T cells. The final relative values were expressed relative to the calibrators as described above; normalized amount of CXCR3
on day 0. Representative data from three independent experiments. Mean   SD, n   6.
Figure 4. Effect of anti-CXCL10
mAb on LN T cells. (a and b) Triple
immunostaining for DEC-205
(brown), BrdU (red), and CD4 (blue)
in the hepatic LNs of control mAb-
(a) and anti-CXCL10 mAb- (b)
treated mice at day 7. The outlined
squares represent clusters between
DEC-205  DCs and CD4  T cells.
Note that there were few BrdU 
CD4  cells in b. Scale bar, 20  m.
The outlines show the B cell follicle
border. F, follicle: PC, paracortex.
(c–e) Triple immunostaining for
B220 (brown), BrdU (red), and
DEC-205 (blue) in the hepatic LNs
at day 0 (c) and day 7 (d and e). (d) In
control mAb-treated LNs, the clus-
ters between DEC-205  cells and
B220 BrdU  cells were seen in the
paracortex. (e) In anti-CXCL10
mAb-treated LNs, only DC accumu-
lations were seen in the paracortex.
The outlined squares represent DC
accumulation. Note that DEC-205 
DCs did not form clusters by them-
selves (square) at day 0. Scale bar, 20
 m. F, follicle; PC, paracortex. (f)
Total cell numbers of LN cells on day
7. (g) The numbers of BrdU CD4 
cells in the paracortex of hepatic LNs
determined by 15-mm2 stained cryo-
sections. (h) DEC-205  cells in the
paracortex of hepatic LNs on day 7
determined by 15-mm2 stained cryo-
sections (top). Densely labeled cells
were analyzed using a grid microme-
ter (reference 25). The number of
grid intersections overlying posi-
tively labeled cells was counted. Final
results were presented as the propor-
tion of the number of positive inter-
sections to the total number of grid
intersections. Primary allogeneic MLR of CD11c  DCs isolated from the hepatic LNs on day 7 (bottom). White column, control mAb-treated mice; black
column, anti-CXCL10 mAb-treated mice; dotted column, untreated mice (f–h). (i) Antigen-specific proliferation of LN T cells obtained from P. acnes–
primed mice treated with control or anti-CXCL10 mAb at day 7. Medium alone, unstimulated LN T cells obtained from P. acnes–primed mice treated with
control mAb at day 7. 10 mice per group were examined. Representative data from three experiments. Mean   SD, n   10. Student’s t test, *P   0.05.1262 Th1 Retention by CXCL10
staining also revealed the dramatic decrease of IFN-  
CD4  T cells at day 7 (data not shown). Anti-CXCL10
treatment did not affect the number or ex vivo alloantigen-
presenting capability of DEC-205  mature DCs (Fig. 4 h),
indicating that the decreased frequency of DC–T cell clus-
ters was not due to increased apoptosis, decreased migration,
or impaired function of DCs. In addition, P. acnes–specific
proliferation of LN T cells obtained from anti-CXCL10
mAb-treated mice at day 7 was not affected (Fig. 4 i).
Increased Infiltration of Proliferating Th1 Cells in the Liver by
Blocking CXCL10. We further pursued the fate of LN
BrdU CD4  T cells, which disappeared from LNs in anti-
CXCL10 mAb-treated mice. Blockade of CXCL10 unex-
pectedly enhanced the inflammatory hepatocellular damage
(Fig. 5 a) accompanied by a significant increase in number
and size of CD4  T cell–associated granulomas (Fig. 5, b
and c) without affecting recruitment of F4/80  macro-
phages/Kupffer cells (Fig. 5, d and e) at day 7. The number
of CD62L CD4  memory T cells (9) was increased in pe-
ripheral blood as well as in the hepatic sinusoid by anti-
CXCL10 mAb (data not shown). Moreover, BrdU CD4 
T cells were also increased both in the liver and the circula-
tion (Fig. 5 f). Liver-infiltrating CD4  T cells isolated from
anti-CXCL10 mAb-treated mice produced higher levels of
IFN-  than control mAb-treated mice without affecting
IL-4 production (Fig. 5 g).
Distinct Expression of Inflammatory Chemokines in the
Liver and Hepatic LNs. Anti-CXCL10 mAb-treatment was
originally expected to inhibit Th1 cell infiltration in the
liver and diminish granuloma formation (22). To solve this,
we compared mRNA expression levels between the liver
and hepatic LNs of three chemokines, CXCL10, CXCL9,
and MIP-1 /CCL3 whose mRNAs all were upregulated
in P. acnes–primed liver (22). CXCL9 and CCL3 mRNAs
were predominantly detected in the liver, but not in the
hepatic LNs (Fig. 6 a), and were not affected by anti-
CXCL10 mAb (data not shown). In contrast, the expres-
sion level of CXCL10 in the hepatic LNs was significantly
higher than in the liver (Fig. 6 a) on day 7 after P. acnes in-
jection. In addition, CXCL10 was produced not by granu-
loma-forming cells but by hepatocytes surrounding granu-
lomas (Fig. 6 b). CXCL9 (Fig. 6 c) and CCL3 (25) were
detected at granuloma-forming cells including Kupffer
cells. These results suggested that Th1 cells still had a ca-
pacity to enter the liver in response to CXCL9 and CCL3
even after blockade with CXCL10. Actually, as expected,
treatment with both anti-CXCL9 and CCL3 polyclonal
Abs resulted in a significant reduction in the size (Fig. 6 d)
and the number of the hepatic granulomas.
Discussion
We have demonstrated that blockade of CXCL10 dra-
matically altered the distribution of BrdU CD4  T cells
(Figs. 4 and 5) in the late phase of P. acnes–induced Th1
granulomatous liver disease (22, 25). Several possibilities
were considered about the role of CXCL10 within the he-
patic LNs. First, CXCL10 directly promoted proliferation of
Figure 5. Effect of anti-CXCL10
mAb on liver injury. (a) Serum ala-
nine transferase levels on d7. (b–e)
Immunostaining for CD4 (red) or
F4/80 (brown) in the control mAb-
treated liver (b and d) and anti-
CXCL10 mAb-treated liver (c and
e) at day 7. Scale bar, 100  m. (f)
The numbers of BrdU CD4  T
cells in the hepatic sinusoid deter-
mined by 15-mm2 stained cryosec-
tions (left) and in the circulation
(right) at day 7. (g) IFN-  and IL-4
productions by sorted liver CD4  T
cells at day 7. White column, con-
trol mAb-treated mice; black col-
umn, anti-CXCL10 mAb-treated
mice (a, f, and g). Representative
data from three independent experi-
ments. Mean   SD, n   10. Stu-
dent’s t test, *P   0.05.1263 Yoneyama et al.
T cells. In this respect, recent investigations suggest that
chemokines produced by antigen-presenting cells directly
influence Th cell differentiation (28). The numbers of liver
F4/80  macrophages (Fig. 5 e) and CD11c  DCs (data not
shown) in this study were not affected by anti-CXCL10
mAb treatment, suggesting that CXCL10 did not recruit
these antigen-presenting cells into the liver and that P. acnes–
antigen loading was not impaired. In addition, alloantigen-
presenting capability of LN DCs as well as antigen-specific
LN T cell proliferation was not impaired by anti-CXCL10
mAb treatment (Fig. 4, h and i). Evidence of increased liver-
infiltrating BrdU CD4  T cells even after treatment with
CXCL10 (Fig. 5 d) also supported the notion that Th cell
proliferation was not directly affected by blockade of
CXCL10. Second, CXCL10 promoted circulating memory
T cell reentry into the hepatic LNs through afferent lym-
phatics from the liver, or through high endothelial venules
(HEVs) from the circulation. However, since CXCL10 was
not produced by HEVs (Fig. 1 d) or afferent lymphatics lo-
cated in the hepatic portal area (data not shown), it is un-
likely that anti-CXCL10 mAb inhibited memory T cell re-
entry across HEVs or along afferent lymphatics.
Third, CXCL10 attracted and retained IFN- –produc-
ing CD4  T cells within the DC–T cell clusters in the he-
patic LNs. In this respect, CCR7 was reported to control T
cell localization within T cell areas of lymphoid tissues (6,
29). Forced expression of CCR7 on in vitro–generated an-
tigen-specific Th2 cells shifted their position from B cell
follicle to T cell areas when adoptively transferred (6),
while transferred CCR7-lacking T cells did not remain
within the T cell areas but extensively localized in B cell
follicle of the spleen (29). In contrast in this study, the
number of BrdU CD4  T cells did not increase within B
cell follicle (Fig. 4, b and e), but significantly increased in
the peripheral blood by blocking CXCL10 (Fig. 5 f). This
suggests that BrdU CD4  T cells egressed the LNs and
entered the circulation. Therefore, the third mechanism
seems to be most probable.
Increased BrdU  memory T cells and probably their
progeny in the peripheral blood by treatment with anti-
CXCL10 mAb may subsequently enter the hepatic sinu-
soid, where the initial antigen took place (25). A larger
number of memory T cells accumulated at granuloma sites
(peripheral DC–T cell clusters; reference 25) by treatment
Figure 6. Effect of inflammatory chemo-
kines on liver injury. (a) Real-time quanti-
tative PCR analysis of CXCL10, CXCL9,
and CCL3 mRNA expressions on the liver
(white bars) and hepatic LNs (black bars) at
day 7. Each amount was normalized to the
level of each GAPDH. The final relative
values were expressed relative to the calibra-
tors (reference 25); normalized amount of
liver for CXCL10, and of LNs for CXCL9
and CCL3. (b and c) Production of
CXCL10 (b, red) by hepatocytes surround-
ing granulomas or CXCL9 (c, red) by gran-
uloma-forming cells at day 7. Scale bar, 100
 m. (d) Effects of anti-CXCL10, CXCL9,
and CCL3 Abs on the size of hepatic granu-
lomas. Mice were injected with anti-
CXCL10 mAbs, anti-CXCL9 pAbs, anti-
CCL3 pAbs, or control rabbit IgG 0, 2 d
after  P. acnes treatment. On day 7, mice
were killed and livers were sampled. Mean
diameters of granulomas (reference 25)
were determined by HE staining of forma-
lin-fixed 2- m thick liver sections. Repre-
sentative data from three independent ex-
periments. Mean   SD, n   6. Student’s
t test, *P   0.05.1264 Th1 Retention by CXCL10
with anti-CXCL10 mAb were in cell cycle (Fig. 5, c and
f), indicating that these cells could proliferate by recluster-
ing with antigen-loaded DCs (25) in the liver. Interest-
ingly, these cells produced higher amount of IFN-  (Fig. 5
g), suggesting that antigen-experienced incompletely polar-
ized CD4  T cells might be further polarized at the liver
after compelled to be released from the draining LNs by
blockade of CXCL10. Although anti-CXCL10 mAb treat-
ment altered the fate of CD4  T cells, the redistributed
CD4  T cells neither migrated toward follicular border
where B cell help occurs (14, 30), nor produced IL-4 in the
liver (Fig. 5, f and g). These suggest that released CD4  T
cells by blockade of CXCL10 were not follicular Th or
Th2 cells. Taking account of several lines of evidence that
P. acnes treatment induces Th1 type immune response (22),
the effect of anti-CXCL10 mAb in the hepatic LNs was
selective on proliferating, IFN- -producing, Th1 type
CD4  T cells.
Our findings identify the actual site of Th1 cell polariza-
tion in vivo in P. acnes–induced granulomatous liver dis-
ease; DC–T cell clusters both in the draining LNs and in
the peripheral inflamed tissue. Therefore, we propose that
Th1 cell generation in this model can be divided into
at least four phases controlled by mature DC-derived
chemokines (Fig. 7). First, initiation of DC–naive T cell
interaction possibly by CCL19, or CCL21 (3, 4, 7). Sec-
ond, amplification of DC–nonpolarized T cell clusters by
CCL22 (and possibly by CXCL10). Third, selective attrac-
tion and retention of T cells that were being in the process
toward Th1 polarization by CXCL10. The last phase is ref-
ormation of DC–Th1 cell clusters at the peripheral tissue
possibly by CCL3 (25) (and also CXCL9) (Fig. 7) to com-
plete Th1 polarization. This also implicates that granuloma
is not mere endpoint of inflammation but a feature of on-
going immune response.
Although cluster-forming nonpolarized T cells progres-
sively shifted to Th1 cells within the LNs (Fig. 2 f), the fre-
quency of BrdU CD4  T cells in the paracortex did not
change from days 2–7 in situ (Fig. 2 d). This would be ex-
plained by the following considerations. Anatomically, the
paracortex is filled with a dense reticular fiber network
(31), in which collagen is sequestered. Therefore, forma-
tion of small granulomatous DC–T cell clusters could de-
velop only within the sparse reticular/collagen spaces (31,
32) that scattered in the deep cortex. Recently proposed
“cytokine fields” as the sites of the polarization of immune
response (33) may develop at such given spaces. In this re-
spect, it was reported that antigen-loaded maturing DCs
produced CCL22 after arriving draining LNs and attracted
activated T cells (13), and that CCL22 mediated antigen-
primed T cell–DC binding (34). In this study, CCL22 was
also expressed by maturing LN DCs probably in the given
spaces and attracted BrdU CD4  T cells (Figs. 1 a and 3 a)
probably to create the local “cytokine field.” Antigen-
experienced initial nonpolarized BrdU  T cells (Fig. 2, d
and f) may migrate toward newly arrived DCs to form a
maximum frequency of DC–T cell clusters at the given
spaces by day 2. Mature DCs are usually eliminated from
the LNs within 48 h after interacting with antigen-specific
T cells (12). This may enable initially primed CD4  T cells
(nonpolarized T cells) to free to migrate toward other sites.
On the other hand, circulating DC precursors in this model
continuously enter the LNs through afferent lymphatics at
least by day 7 (25). Thus, from days 2–7, newly arriving
DCs might enter the extinguished “cytokine fields” and se-
lectively attract IFN- -producing, but not IL-4–producing
Figure 7. Peripheral and re-
gional DC–Th cell clusters as the
sites of Th1 cell generation reg-
ulated by DC-derived chemo-
kines. (1) Initiation and induc-
tion of DC-naive T cell clusters
by CCL19 or CCL21 (refer-
ences 3, 4, and 7). (2) Amplifica-
tion of DC-nonpolarized T cell
clusters by CCL22 (references
13, 34, and this study). (3) Pro-
motion and retention of DC–
Th1 cell clusters (this study).
These clusters may develop in
the given spaces of the paracortex
called “cytokine fields” (refer-
ence 33). DC-derived chemo-
kines may regulate T cell traffic
depending on their state of acti-
vation between these given
spaces to magnify the effective
immune responses. After leav-
ing the LNs, Th1 cells migrate
into the liver through the circu-
lation and (4) reform clusters
with peripheral tissue-resided in-
flammatory DCs (granuloma formation) possibly by CCL3 or CXCL9 (references 22, 25, and this study). Th1 cells can further proliferate and produce
higher amount of IFN-  at the periphery of the granulomas to complete polarization.1265 Yoneyama et al.
subset among the freed primed CD4  T cells by producing
CXCL10. In other words, like CD8  T cell competition
to antigen-presenting cells (35), activated CXCR3 CD4 
T cells might compete for access to CXCL10-producing
mature DCs according to their extent of IFN-  production
between the established “cytokine fields.”
CXCL10-mediated effector T cell traffic pattern is also
interesting. In Toxoplasma gondii infection, Khan et al. (20)
reported that neutralization of CXCL10 inhibited the in-
filtration of effector Th1 cells and ability to kill the parasite
in the target organs such as the liver, spleen, brain, and
lung. The effect on the Th1 cell trafficking into the target
tissues is opposite to our results. However, this could be
explained by the distinct response to different stimuli ac-
cording to the disease models, since gene expression of
inflammatory chemokines including CXCL10 is induced
in tissue-, cell type–, and stimulus-specific manner (17–
22, 36, 37). Inflammatory chemokines including CCL3,
CXCL9, and CXCL11 were generally produced by gran-
uloma-forming Kupffer cells in our model (references 22
and 25; Fig. 6, and data not shown). Since Kupffer cells di-
rectly abut the blood stream, CCL3 and CXCL9 may pro-
mote blood T cell entry into the hepatic sinusoid and may
help them to transmigrate into Disse’s space (25, 38). On
the other hand, CXCL10 was preferentially produced by
injurious hepatocytes (Fig. 6), whose vascular poles abut-
ted Disse’s space. T cells that transmigrated into Disse’s
space may be sequentially attracted into the tissue space by
CXCL10. In this respect, sequential involvement of differ-
ent chemokines for leukocyte entry and subsequent mobi-
lization in the tissue has been also demonstrated in in-
flamed tonsils and skin (39). Therefore, direct effect of
CXCL10 for blood T cell entry into the sinusoid is con-
sidered to be weak compared with CCL3 and CXCL9. In
addition, the expression of CXCL10 mRNA was much
higher in the LNs than that in the liver (Fig. 6). Thus, the
effect of CXCL10 mAb treatment in this model was
mostly on the LNs, and released cells in the process of Th1
polarization bearing CXCR3 alone or both CXCR3 and
CCR5 (22) could be recruited to the sinusoid by CCL3
and CXCL9 (Fig. 6). In contrast, in T. gondii infection as
well as acute allograft rejection in cardiac transplantation,
CXCL10 was rapidly and strongly expressed in the target
organs (20, 36, 37) especially by endothelial cells (37) that
may directly promote leukocyte entry from the circula-
tion. The expressions of CXCL9, CXCL11, and CCL3 in
the target organs in these models were reported to be de-
layed and weak or none compared with CXCL10 (20, 36,
37), and the effect of CXCL10 neutralization was mostly
on the target tissues. Either CXCL9 or CCL3 did not sub-
stitute for CXCL10 in T cell recruitment. Therefore, we
consider that effector T cell traffic into the target organs
may be determined by the expression level and tissue lo-
calization of chemokines between lymphoid and nonlym-
phoid organs. Despite the opposite effect on T cell traffic
into the target organs, the consensus is that CXCL10 plays
a pivotal role in controlling effector Th1 cell mobilization
in host defense system.
The biological significance of CXCL10-mediated Th1
cell retention could be of host protection. The final out-
come of T cell–mediated disease is dependent on the ex-
tent and duration of effector T cell recruitment into the
target tissue. Although appropriate Th1 cell traffic into the
inflamed liver is necessary to eliminate microorganism (25),
excessive influx of Th1 cells may cause more severe inflam-
mation (Fig. 5 a). CXCL10 may play a role in supplying an
appropriate number of effector T cells to the circulation.
This should enable the host to eradicate an invading patho-
gen with minimum tissue damage.
In conclusion, we have demonstrated in this study that
DC-derived CXCL10 regulates DC–Th1 cell cluster for-
mation and retention of CD4  T lymphocytes that are be-
ing in the process of Th1 polarization in the T cell areas of
draining LNs. Our study suggests that release of memory T
lymphocytes into efferent lymphatics as well as homing to
inflamed tissue are controlled by chemokines. The concept
of “Th1 cell retention” as host protective immunity may
provide a new insight into the mechanism of effector T cell
generation as well as the development of novel therapeutic
approaches to Th1-mediated diseases.
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